CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $511,091 | -18.2% | 11,260 | +1.2% | 0.05% | -34.2% |
| Q2 2023 | $624,838 | +18.2% | 11,130 | -4.8% | 0.07% | +15.9% |
| Q1 2023 | $528,648 | +10.8% | 11,688 | -0.4% | 0.06% | 0.0% |
| Q4 2022 | $476,906 | -44.0% | 11,732 | -10.0% | 0.06% | -51.2% |
| Q3 2022 | $852,000 | +5.8% | 13,034 | -1.6% | 0.13% | +7.5% |
| Q2 2022 | $805,000 | -3.0% | 13,250 | +0.2% | 0.12% | +10.1% |
| Q1 2022 | $830,000 | -14.5% | 13,224 | +3.2% | 0.11% | -15.5% |
| Q4 2021 | $971,000 | +5010.5% | 12,820 | +7441.2% | 0.13% | +4200.0% |
| Q3 2021 | $19,000 | -29.6% | 170 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $27,000 | +440.0% | 170 | +400.0% | 0.00% | +200.0% |
| Q4 2020 | $5,000 | -99.8% | 34 | +70.0% | 0.00% | 0.0% |
| Q3 2020 | $2,196,000 | +20.8% | 20 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,818,000 | +114.4% | 20 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $848,000 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |